Curated News
By: NewsRamp Editorial Staff
December 29, 2025
Trump Reclassifies Cannabis to Schedule III in Historic Policy Shift
TLDR
- Cannabis companies like Tilray Brands Inc. gain a competitive edge as federal reclassification from Schedule I to III reduces regulatory barriers and opens new market opportunities.
- President Trump's executive order moved cannabis from Schedule I, which has no accepted medical use, to Schedule III, altering federal drug policy and regulatory frameworks.
- This reclassification advances medical cannabis access, potentially improving patient care and reducing stigma, contributing to a more progressive and compassionate healthcare system.
- Cannabis now sits alongside substances like Tylenol with codeine on Schedule III, marking a historic shift in U.S. drug policy after decades of restriction.
Impact - Why it Matters
This federal reclassification represents a watershed moment for cannabis policy with far-reaching implications. For patients, it validates medical cannabis use and could accelerate research into therapeutic applications. For businesses, it may ease banking restrictions, reduce tax burdens under IRS code 280E, and stimulate investment in the growing legal cannabis market. For states, it provides federal validation for medical marijuana programs and could encourage more states to adopt similar policies. This shift reflects changing public attitudes and scientific understanding about cannabis, potentially paving the way for further reforms including possible federal legalization.
Summary
In a landmark shift in U.S. drug policy, cannabis has been officially reclassified from Schedule I to Schedule III of the Controlled Substances Act following a recent executive order by President Donald Trump. This historic move recognizes that marijuana has accepted medical uses, removing it from the most restrictive category reserved for substances like heroin that are deemed to have no therapeutic value. The federal policy evolution is creating significant momentum across the country, with Tennessee lawmakers now considering medical cannabis reform as the federal stance shifts, potentially opening the door for more states to revisit their marijuana policies.
The reclassification has immediate implications for major cannabis companies like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY), which will be closely tracking debates and legislative developments across the United States in the wake of this federal change. Industry observers are watching how this regulatory shift might impact financial markets and investment opportunities in the legalized cannabis sector. For those following these developments, CNW420 provides daily updates on the latest milestones in the fast-changing world of cannabis, releasing concise, informative content each business day at 4:20 p.m. Eastern as a tribute to cannabis culture.
This policy change represents more than just bureaucratic reshuffling—it signals a fundamental shift in how the federal government views cannabis, potentially easing research restrictions, banking limitations, and tax burdens that have hampered the industry's growth. As the regulatory landscape evolves, investors and industry participants can stay informed through resources like CannabisNewsWire, which offers comprehensive coverage of how these developments may impact markets. The move from Schedule I to Schedule III marks a pivotal moment in the decades-long debate over cannabis policy, with ripple effects expected across medical research, business operations, and state-level legislation throughout the country.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Trump Reclassifies Cannabis to Schedule III in Historic Policy Shift
